Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Merus N.V. MRUS
$20.11
-$0.72 (-3.60%)
На 18:00, 12 мая 2023
+49.18%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
961561049.00000000
-
week52high
30.81
-
week52low
12.03
-
Revenue
29604000
-
P/E TTM
-6
-
Beta
0.75432500
-
EPS
-2.88000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Citigroup | Buy | Buy | 17 авг 2022 г. |
| Stifel | Buy | 02 авг 2022 г. | |
| Guggenheim | Buy | Buy | 18 июл 2022 г. |
| Citigroup | Buy | Buy | 19 мая 2022 г. |
| BMO Capital | Outperform | 11 февр 2022 г. | |
| SVB Leerink | Outperform | Outperform | 13 окт 2022 г. |
| Citigroup | Buy | Buy | 16 ноя 2022 г. |
| SVB Leerink | Outperform | Outperform | 04 ноя 2022 г. |
| Needham | Buy | Buy | 04 ноя 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 04 ноя 2022 г. |
| EF Hutton | Buy | 05 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Shuman Harry | A | 19000 | 19000 | 02 февр 2023 г. |
| Joe Andrew | A | 104000 | 104000 | 02 февр 2023 г. |
| Lundberg Sven Ante | A | 380000 | 380000 | 02 февр 2023 г. |
| Silverman Peter B. | A | 104000 | 104000 | 02 февр 2023 г. |
| Liu Hui | A | 104000 | 104000 | 02 февр 2023 г. |
| Silverman Peter B. | A | 20000 | 20000 | 04 янв 2023 г. |
| Shuman Harry | D | 3517 | 168 | 13 дек 2022 г. |
| Shuman Harry | D | 5000 | 2500 | 01 дек 2022 г. |
| Shuman Harry | D | 3685 | 575 | 01 дек 2022 г. |
| Shuman Harry | A | 4260 | 2500 | 01 дек 2022 г. |
Новостная лента
Here's Why Merus N.V. (MRUS) is a Great Momentum Stock to Buy
Zacks Investment Research
11 мая 2023 г. в 13:44
Does Merus N.V. (MRUS) have what it takes to be a top stock pick for momentum investors?
Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
04 мая 2023 г. в 22:02
Merus N.V. (MRUS) came out with a quarterly loss of $0.86 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $0.43 per share a year ago.
Merus: Dutch Drug Developer With An Interesting Platform
Seeking Alpha
04 апр 2023 г. в 09:28
Merus N.V. develops bispecific and trispecific antibodies for cancer. They have deals with an array of big pharma.
Is a Surprise Coming for Merus (MRUS) This Earnings Season?
Zacks Investment Research
23 февр 2023 г. в 12:48
Merus (MRUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Strength Seen in Merus N.V. (MRUS): Can Its 12.6% Jump Turn into More Strength?
Zacks Investment Research
10 февр 2023 г. в 05:16
Merus N.V. (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.